ストックスクリーナーアプリを入手
46.51
0.49%
-0.23
前日終値:
$46.74
開ける：
$47.05
24時間の取引高:
2.14M
Relative Volume:
0.71
時価総額：
$8.83B
収益：
$217.77M
当期純損益:
$-438.86M
株価収益率:
-19.30
EPS:
-2.41
ネットキャッシュフロー:
$-456.33M
1週間 パフォーマンス:
+0.09%
1か月 パフォーマンス:
+16.27%
6か月 パフォーマンス:
+37.64%
1年 パフォーマンス:
+79.37%
1日の値動き範囲:
$46.13
$47.36
1週間の範囲:
$46.13
$48.68
52週間の値動き範囲:
$21.72
$48.68
Bridgebio Pharma Inc Stock (BBIO) Company Profile
BBIO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
46.51 | 8.82B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-14 | 開始されました | Jefferies | Buy |
| 2025-07-09 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-06-17 | 開始されました | Wolfe Research | Outperform |
| 2025-03-31 | 開始されました | Redburn Atlantic | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-10-03 | 開始されました | Oppenheimer | Perform |
| 2024-09-04 | 開始されました | Piper Sandler | Overweight |
| 2024-03-21 | 再開されました | Raymond James | Outperform |
| 2024-01-31 | 開始されました | BMO Capital Markets | Market Perform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-11-07 | 開始されました | Citigroup | Buy |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-07-18 | ダウングレード | Jefferies | Buy → Hold |
| 2023-04-19 | 開始されました | Evercore ISI | Outperform |
| 2023-02-06 | 開始されました | Cowen | Outperform |
| 2021-12-27 | 繰り返されました | Mizuho | Buy |
| 2021-12-27 | 繰り返されました | SVB Leerink | Outperform |
| 2021-09-10 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-03-22 | 繰り返されました | Goldman | Buy |
| 2021-02-22 | 再開されました | JP Morgan | Overweight |
| 2021-02-09 | 再開されました | Goldman | Buy |
| 2021-01-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-10 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-25 | 開始されました | BofA/Merrill | Neutral |
| 2020-05-19 | 開始されました | BTIG Research | Buy |
| 2020-04-13 | 開始されました | H.C. Wainwright | Buy |
| 2020-02-19 | 開始されました | Mizuho | Buy |
| 2019-07-26 | 開始されました | Raymond James | Outperform |
| 2019-07-22 | 開始されました | BMO Capital Markets | Outperform |
| 2019-07-22 | 開始されました | Goldman | Buy |
| 2019-07-22 | 開始されました | JP Morgan | Overweight |
| 2019-07-22 | 開始されました | Jefferies | Buy |
| 2019-07-22 | 開始されました | Piper Jaffray | Overweight |
| 2019-07-22 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Bridgebio Pharma Inc (BBIO) 最新ニュース
What analysts say about BridgeBio Pharma Inc. stockSky-high return potential - Autocar Professional
What drives BridgeBio Pharma Inc. stock priceOutstanding capital growth - Jammu Links News
Is BridgeBio Pharma Inc. a good long term investmentFree Stock Selection - Jammu Links News
BridgeBio Pharma stock maintains Buy rating at H.C. Wainwright after royalty deal - Investing.com Canada
These 2 Momentum Stocks Got a Bullish Nod — Here’s Why They Could Reach New Highs - The Globe and Mail
Jefferies Initiates BridgeBio Pharma(BBIO.US) With Buy Rating, Announces Target Price $70 - 富途牛牛
Scotiabank Sticks to Its Buy Rating for BridgeBio Pharma (BBIO) - The Globe and Mail
Citi reiterates Buy rating on BridgeBio stock ahead of key trial data - Investing.com Canada
Trading (BBIO) With Integrated Risk Controls - news.stocktradersdaily.com
BridgeBio Pharma (BBIO) Receives Buy Rating from Jefferies | BBIO Stock News - GuruFocus
Citi Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $67 - 富途牛牛
Jefferies Initiates Coverage of BridgeBio Pharma (BBIO) with Buy Recommendation - MSN
BridgeBio Pharma stock initiated with Buy rating at Jefferies on Attruby potential - Investing.com Canada
BridgeBio Pharma's BBP-418: A Promising Investment in Groundbreaking LGMD2I/R9 Therapy - AInvest
BridgeBio (BBIO) Tanks After Selling Beyonttra Royalty Rights - MSN
Helix shareholders to vote on BridgeBio Oncology merger on August 4 By Investing.com - Investing.com Nigeria
Helix shareholders to vote on BridgeBio Oncology merger on August 4 - Investing.com Australia
Cancer-Focused BridgeBio's $949M SPAC Deal Gets SEC Nod - Law360
BridgeBio Oncology's SPAC Merger Advances: SEC Clears Path for Novel Cancer Drug Development Platform - Stock Titan
BridgeBio Pharma stock hits 52-week high, reaching $45.53 By Investing.com - Investing.com South Africa
BridgeBio Pharma Inc. Rockets on Strategic Moves - StocksToTrade
BridgeBio Pharma stock hits 52-week high, reaching $45.53 - Investing.com Australia
Oppenheimer Upgrades BridgeBio Pharma to Outperform From Market Perform, Price Target is $60 - MarketScreener
BridgeBio Pharma (BBIO) Receives Rating Upgrade to Outperform | BBIO Stock News - GuruFocus
BridgeBio (BBIO) Shares Upgraded with Positive Outlook on Future Sales | BBIO Stock News - GuruFocus
BridgeBio (BBIO) Upgraded to Outperform with New Price Target | BBIO Stock News - GuruFocus
BridgeBio Pharma Raises $300M Through Partial European Royalty Monetization for BEYONTTRA - MSN
High Growth Tech Stocks To Watch In The US July 2025 - simplywall.st
BridgeBio Pharma’s SWOT analysis: stock poised for growth on strong pipeline - Investing.com
BridgeBio Pharma (BBIO) Opinions on $300 Million Royalty Financing Deal - Quiver Quantitative
BridgeBio Pharma Enters Royalty Purchase Agreement - TipRanks
Latham & Watkins Advises BridgeBio on US$300 Million Strategic Royalty Sale of BEYONTTRA® European Royalties - Latham & Watkins LLP
Viking Global Investors sells $154 million in BridgeBio Pharma (BBIO) By Investing.com - Investing.com
Analysts Are Bullish on These Healthcare Stocks: Aardvark Therapeutics, Inc. (AARD), BridgeBio Pharma (BBIO) - The Globe and Mail
BridgeBio Pharma director Valantine buys shares worth $30,027 - Investing.com
BridgeBio Pharma Sells Part of Beyonttra Royalty Rights for $300 Million - MarketScreener
BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty | BBIO Stock News - GuruFocus
BridgeBio's Strategic Royalty Deal: A Masterclass in Capital Optimization - AInvest
BridgeBio Pharma's Russell Exclusion: A Hidden Growth Catalyst for Biotech Investors? - AInvest
Wolfe Research Initiates Coverage of BridgeBio Pharma (BBIO) with ‘Outperform’ Rating - MSN
BridgeBio (BBIO) Schedules Investor Webinar on Limb-Girdle Muscu - GuruFocus
BridgeBio (BBIO) Schedules Investor Webinar on Limb-Girdle Muscular Dystrophy | BBIO Stock News - GuruFocus
BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET - Yahoo Finance
BridgeBio Pharma (BBIO) Maintains Buy Rating; Price Target Raised | BBIO Stock News - GuruFocus
BridgeBio Pharma (BBIO) Gets a Buy from TD Cowen - The Globe and Mail
Piper Sandler Reaffirms Overweight Rating on BridgeBio Ahead of Phase 3 CALIBRATE Results - Insider Monkey
10 Biotech Stocks Screaming a Buy - Insider Monkey
Wolfe Research Initiates Coverage on BBIO with Outperform Rating - GuruFocus
Wolfe Research Initiates Coverage on BBIO with Outperform Rating | BBIO Stock News - GuruFocus
BridgeBio (BBIO) Gains Positive Outlook with Strong Transthyreti - GuruFocus
Wolfe Research Initiates Coverage on BridgeBio Pharma With Outperform Rating, $49 Price Target - MarketScreener
Bridgebio Pharma Inc (BBIO) 財務データ
収益
当期純利益
現金流量
EPS
Bridgebio Pharma Inc (BBIO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Kumar Neil | Chief Executive Officer |
Jul 01 '25 |
Sale |
42.54 |
40,000 |
1,701,400 |
975,686 |
| VIKING GLOBAL INVESTORS LP | 10% Owner |
Jun 27 '25 |
Sale |
44.00 |
3,500,000 |
154,000,000 |
18,555,375 |
0.59%
0.34%
大文字化:
|
ボリューム (24 時間):